12:00 AM
Mar 18, 2002
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zadaxin thymosin alpha 1 plus interferon: Phase II results; Phase III

Twelve-month follow-up data from a Turkish Phase II trial in 31 patients with chronic HBV showed that 71% (15/21) of patients treated with Zadaxin plus alpha interferon from Schering-Plough Corp. (SGP, Kenilworth, N.J.) maintained...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >